{
 "id": "rheumatoid-arthritis",
 "name": "Rheumatoid arthritis",
 "aliases": [
  "Rheumatoid arthritis (RA)"
 ],
 "acronyms": [
  "RA"
 ],
 "bodySystem": "immune",
 "parent": null,
 "children": [],
 "edition": "2026-11",
 "merkleRoot": "006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6",
 "builtFrom": "program.status and program.eligibility facts, grouped by the condition registry",
 "counts": {
  "open": 0,
  "limited": 0,
  "waitlist": 0,
  "closed": 1
 },
 "funds": [
  {
   "fund": "Rheumatoid arthritis (RA)",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": 4000,
   "insuranceTypes": [
    "Medicaid",
    "Medicare",
    "TRICARE"
   ],
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  }
 ],
 "drugsWhoseLabelNamesThisCondition": [
  {
   "ingredient": "ABATACEPT",
   "pages": [
    {
     "brand": "Orencia",
     "url": "https://omnirx.org/negotiated-drugs/orencia"
    }
   ],
   "labelSentence": "... the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%220836c6ac-ee37-5640-2fed-a3185a0b16eb%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "RA Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/rheumatoid-arthritis-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Bristol Myers Squibb Patient Assistance Foundation",
     "url": "https://www.bmspaf.org/#/medicines",
     "programPageIsExternal": true,
     "inCurrentList": true,
     "note": null,
     "listKind": "Medicines available through the Foundation",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": null,
    "effective": "2028-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "ETANERCEPT",
   "pages": [
    {
     "brand": "Enbrel",
     "url": "https://omnirx.org/negotiated-drugs/enbrel"
    }
   ],
   "labelSentence": "Rheumatoid Arthritis (RA) ( 1.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22a002b40c-097d-47a5-957f-7a7b1807af7f%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Enbrel Support (via Amgen)",
     "url": "https://omnirx.org/assistance/enbrel-patient-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "RA Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/rheumatoid-arthritis-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Amgen Safety Net Foundation",
     "url": "https://www.amgensafetynetfoundation.com/eligibility.html",
     "programPageIsExternal": true,
     "inCurrentList": true,
     "note": null,
     "listKind": "Eligibility page medication selector (tile titles)",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": 2418.7,
    "effective": "2027-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "TOFACITINIB",
   "pages": [
    {
     "brand": "Xeljanz",
     "url": "https://omnirx.org/negotiated-drugs/xeljanz"
    }
   ],
   "labelSentence": "Moderately to severely active rheumatoid arthritis (RA), who have had an inadequate response or intolerance to one or more TNF blockers.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22253635c8-1ea7-41ba-b216-dea5e3305c47%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Pfizer RxPathways",
     "url": "https://omnirx.org/assistance/pfizer-rxpathways",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": "no new patients starting July 1, 2026",
     "listKind": "products remaining within Pfizer PAP as of January 1, 2026",
     "status": "limited",
     "statusRead": "2026-11-07"
    },
    {
     "name": "RA Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/rheumatoid-arthritis-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": null,
    "effective": "2028-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "Adalimumab",
   "pages": [
    {
     "brand": "Humira",
     "url": "https://omnirx.org/medicines/humira"
    }
   ],
   "labelSentence": "Rheumatoid Arthritis (RA) ( 1.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%222488b0bc-7b8f-4cc8-91ea-48e7ea5e8915%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Humira Complete (via myAbbVie Assist)",
     "url": "https://omnirx.org/assistance/humira-patient-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "myAbbVie Assist",
     "url": "https://omnirx.org/assistance/abbvie-myabbvie-assist",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Available medicines (myAbbVie Assist)",
     "status": null,
     "statusRead": null
    },
    {
     "name": "RA Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/rheumatoid-arthritis-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Cyclosporine",
   "pages": [
    {
     "brand": "Restasis",
     "url": "https://omnirx.org/medicines/restasis"
    }
   ],
   "labelSentence": "Rheumatoid Arthritis Cyclosporine capsules (modified) is indicated for the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to ...",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%221952d4c7-a40e-4924-b669-c41400774cb9%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "myAbbVie Assist",
     "url": "https://omnirx.org/assistance/abbvie-myabbvie-assist",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Available medicines (myAbbVie Assist)",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Golimumab",
   "pages": [
    {
     "brand": "Simponi",
     "url": "https://omnirx.org/medicines/simponi"
    }
   ],
   "labelSentence": "Adult patients with moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate ( 1.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%229e260a47-55af-4c92-8d88-a86ccc767fff%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Johnson & Johnson Patient Assistance Program",
     "url": "https://omnirx.org/assistance/johnson-and-johnson-pap",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Medicines in the Quick Reference Guide picker on the program page",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Sarilumab",
   "pages": [
    {
     "brand": "Kevzara",
     "url": "https://omnirx.org/medicines/kevzara"
    }
   ],
   "labelSentence": "... adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22827bc01c-d379-4266-a18c-c7f904b76af3%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "RA Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/rheumatoid-arthritis-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Tocilizumab",
   "pages": [
    {
     "brand": "Actemra",
     "url": "https://omnirx.org/medicines/actemra"
    }
   ],
   "labelSentence": "Rheumatoid Arthritis (RA) ( 1.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%2200529b23-850a-42b9-a152-125a95b5242c%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Genentech Patient Foundation",
     "url": "https://omnirx.org/assistance/genentech-access-solutions",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": "stops accepting new enrollments effective January 1, 2027; all Foundation support ends December 31, 2027",
     "listKind": "Our Participating Medicines",
     "status": null,
     "statusRead": null
    },
    {
     "name": "RA Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/rheumatoid-arthritis-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Upadacitinib",
   "pages": [
    {
     "brand": "Rinvoq",
     "url": "https://omnirx.org/medicines/rinvoq"
    }
   ],
   "labelSentence": "RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%222966aec7-2ef0-923c-d8ff-fe1a957bf095%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Rinvoq Complete (via AbbVie)",
     "url": "https://omnirx.org/assistance/rinvoq-patient-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "myAbbVie Assist",
     "url": "https://omnirx.org/assistance/abbvie-myabbvie-assist",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Available medicines (myAbbVie Assist)",
     "status": null,
     "statusRead": null
    },
    {
     "name": "RA Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/rheumatoid-arthritis-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "CERTOLIZUMAB PEGOL",
   "pages": [
    {
     "brand": "Cimzia",
     "url": "https://omnirx.org/negotiated-drugs/cimzia"
    }
   ],
   "labelSentence": "Treatment of adults with moderately to severely active rheumatoid arthritis ( 1.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22b4c2c9dc-a0bb-4d64-a667-a67ebe88392d%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": null,
    "effective": "2028-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "Corticotropin",
   "pages": [
    {
     "brand": "Acthar",
     "url": "https://omnirx.org/medicines/acthar"
    }
   ],
   "labelSentence": "Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy);",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22110a17aa-6ed9-4458-8e67-1a742ce448e4%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Infliximab",
   "pages": [
    {
     "brand": "Remicade",
     "url": "https://omnirx.org/medicines/remicade"
    }
   ],
   "labelSentence": "Rheumatoid Arthritis in combination with methotrexate : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with ...",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22a0a046c1-056d-45a9-bfd9-13b47c24f257%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  }
 ],
 "fundsForRelatedCosts": [],
 "note": "Each status is what the fund page said on readOn. It is not an eligibility determination. We hold only the organizations we read; no fund here does not mean no fund exists.",
 "licence": "CC BY 4.0 for the OmniRx compilation"
}